RET rearrangements are actionable alterations in breast cancerBhavna Paratala, Kim M. Hirshfield, Jon Chung et al.|Nature Communications|2018Cited by 127
Down’s Syndrome and Triple Negative Breast Cancer: A Rare Occurrence of Distinctive Clinical RelationshipNandini Dey, Brian Leyland‐Jones, Jessica Klein et al.|International Journal of Molecular Sciences|2017Cited by 9
Results of a phase Ib trial evaluating the safety and clinical activity of sapanisertib (TAK 228) in combination with serabelisib (TAK 117) and paclitaxel in patients with advanced ovarian, endometrial, or breast cancer.Casey Williams, Luis Rojas‐Espaillat, Kirstin Williams et al.|Journal of Clinical Oncology|2020Cited by 9
Abstract 4591: Estrogen receptor-positive breast cancer: from genomic landscape to treatment approachPradip De, Brian Leyland‐Jones, Casey Williams et al.|Cancer Research|2016Cited by 1
Abstract PD4-15: A tale of two pathways: Mutations in PI3K pathway in TNBC patients matter for the oncogenic cooperation with DNA damage repair pathwayNandini Dey, Brian Leyland‐Jones, Casey Williams et al.|Cancer Research|2018Cited by 0